← Ablatotech Signals
Immunology SignalsArticle

A putative therapeutic target in psoriatic arthritis: P01374

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
July 10, 2026 · Lead editor: ImmunologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — P01374 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in psoriatic arthritis.

# Signals Article on Putative Target P01374 for Psoriatic Arthritis

Background

The protein encoded by the putative target P01374 has emerged as a candidate of interest in the context of psoriatic arthritis, a chronic inflammatory disease characterized by joint inflammation and skin lesions. Preliminary data suggest that P01374 may play a significant role in the inflammatory pathways associated with psoriatic arthritis, indicating its potential as a therapeutic target. Given the complexity of this disease, further investigation into the molecular mechanisms involving this protein is essential for developing effective treatment strategies.

Data-mining rationale

Our analysis employed the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "psoriatic arthritis" against 12 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:P01374 was identified as being present in several expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in psoriatic arthritis and underscores the need for further exploration.

Why prior analyses may have missed this

Many of the GEO datasets analyzed predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of P01374 in the context of psoriatic arthritis. The absence of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in psoriatic arthritis.

Reasoning for further validation

To substantiate the potential role of P01374 in psoriatic arthritis, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including P01374, by quantitative PCR (qPCR) in an independent cohort of psoriatic arthritis patients to confirm expression patterns. 3. Investigate the tissue specificity of P01374 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in joint and skin tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize P01374 within known biological pathways related to inflammation and psoriatic arthritis. 5. If validation is achieved, assess the druggability of P01374 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.

References

  • [UniProt: P01374](https://www.uniprot.org/uniprot/P01374)
  • [UniProt: P01375](https://www.uniprot.org/uniprot/P01375)
  • [UniProt: Q29983](https://www.uniprot.org/uniprot/Q29983)
  • [UniProt: P01889](https://www.uniprot.org/uniprot/P01889)
  • [UniProt: Q9NZH7](https://www.uniprot.org/uniprot/Q9NZH7)
  • [NCBI GEO Accession GDS:200234831](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200234831)
  • [NCBI GEO Accession GDS:200142049](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200142049)
  • [NCBI GEO Accession GDS:200141934](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200141934)
  • [NCBI GEO Accession GDS:200137634](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200137634)
  • [NCBI GEO Accession GDS:200100648](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200100648)

References

  1. UniProtKB. Entry P01374. The UniProt Consortium. [link]
  2. UniProtKB. Entry P01375. The UniProt Consortium. [link]
  3. UniProtKB. Entry Q29983. The UniProt Consortium. [link]
  4. UniProtKB. Entry P01889. The UniProt Consortium. [link]
  5. UniProtKB. Entry Q9NZH7. The UniProt Consortium. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications